Alzecure Pharma Stock Gross Profit
| ALZCUR Stock | SEK 1.19 0.16 15.53% |
AlzeCure Pharma fundamentals help investors to digest information that contributes to AlzeCure Pharma's financial success or failures. It also enables traders to predict the movement of AlzeCure Stock. The fundamental analysis module provides a way to measure AlzeCure Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AlzeCure Pharma stock.
AlzeCure |
AlzeCure Pharma Company Gross Profit Analysis
AlzeCure Pharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, AlzeCure Pharma reported 0.0 of gross profit. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The gross profit for all Sweden stocks is 100.0% higher than that of the company.
AlzeCure Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AlzeCure Pharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AlzeCure Pharma could also be used in its relative valuation, which is a method of valuing AlzeCure Pharma by comparing valuation metrics of similar companies.AlzeCure Pharma is currently under evaluation in gross profit category among its peers.
AlzeCure Fundamentals
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 173.51 M | |||
| Shares Outstanding | 59.19 M | |||
| Shares Owned By Insiders | 41.31 % | |||
| Shares Owned By Institutions | 6.48 % | |||
| Price To Book | 6.62 X | |||
| EBITDA | (77.2 M) | |||
| Net Income | (77.78 M) | |||
| Cash And Equivalents | 222.05 M | |||
| Cash Per Share | 5.88 X | |||
| Current Ratio | 48.05 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (70.64 M) | |||
| Earnings Per Share | (1.78) X | |||
| Target Price | 11.88 | |||
| Number Of Employees | 14 | |||
| Beta | 0.76 | |||
| Market Capitalization | 254.44 M | |||
| Total Asset | 45.65 M | |||
| Z Score | -3.3 | |||
| Net Asset | 45.65 M |
About AlzeCure Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AlzeCure Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AlzeCure Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AlzeCure Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in AlzeCure Stock
AlzeCure Pharma financial ratios help investors to determine whether AlzeCure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AlzeCure with respect to the benefits of owning AlzeCure Pharma security.